reason report
portfolio transit underway investor await tripl select
result modestli beat consensu revenu ep
driven strong symdeko uptak us lower
revenu beat consensu estim
grow yoy decreas sequenti due
channel inventori build previou quarter higher gross net
adjust quarter symdeko launch captur signific
convers new start momentum continu
next quarter better doublet take us market
expect compani reiter full year product revenu
guidanc bracket estim
consensu non-gaap sg
expens guidanc initi guidanc
bracket estim consensu
vertex state previous conserv guidanc reflect
anticip revenu region reimburs place
addit reimburs agreement could provid upsid
revenu howev compani fail make meaning progress
reimburs negoti major eu market franc
england cap growth upper end guidanc
bright side vertex report excel phase data second
tripl combin tezacaftor ivacaftor march
compani seem well track us nda eu
regulatori file either tripl combin regim
final data releas expect
cf revenu larg in-lin expect price target
updat revenu expens forecast base
recent quarter commentari total revenu forecast decreas
remain larg unchang
chang primarili base slightli slower revenu
trajectori kalydeco us sale revenu estim
 partial off-set slightli higher symdeko ex-u sale
revis total revenu forecast consensu
oper expens estim lower
due lower sg forecast partial off-set slightli higher
estim base chang pro-forma dilut ep estim
virtual unchang decreas virtual
unchang increas revis
ep estim consensu
consensu revis price target
maintain market perform rate
average ep revenu multipl
dcf wacc tg
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million ep dilut exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
price target vertex rate stock market perform vertex
clear clinic develop hurdl introduc medicin treat
patient cystic fibrosi cf believ market fairli valu vertex cf
portfolio loss exclus vertex launch success iter cf
medicin cloud disput price access delay reimburs
europ result success reduct revenu forecast compani
expect vertex cf revenu line grow steadili
consensu expect still robust perform compar
consensu expect believ vertex geograph revenu mix continu
heavili weight us due continu resist payer
europ dynam put current consensu medium-term revenu estim risk
probabl success tripl combin valuat account
full expect valu cf portfolio well risk-adjust opportun compani
effort antitrypsin defici aatd even posit view new dcf
valuat incorpor sustain oper margin
requir consider disciplin compani reput frugal
incorpor premium price target recogn vertex
might one attract larg cap growth asset sector howev view
reason acquisit premium would put compani cost nearli like
difficult pill swallow dilution-avers larg compani
revenu beat driven higher expect outsid us symdeko sale vertex
total cf product revenu beat consensu beat forecast
global symdeko sale ahead estim ahead
consensu grew qoq orkambi kalydeco sequenti due channel
inventori build previou quarter increas gross net adjust quarter
stronger expect symdeko sale driven initi sale outsid
us primarili germani contribut increas balanc
compani indic demand symdeko germani follow pattern
us come patient previous discontinu never initi orkambi switcher
orkambi kalydeco appear fear cannib orkambi symdeko
us stabil although clear whether switch symdeko acceler
near futur sale kalydeco consensu
estim sale orkambi consensu
estim
ep beat driven higher revenu in-lin oper expens gross margin
line estim higher consensu vertex non-gaap total
oper expens consensu forecast non-
 expens consensu estim
non-gaap sg also consensu estim
compani tax rate slightli higher consensu estim
non-gaap dilut ep come consensu estim
guidanc reiter compani reiter full year product revenu guidanc
bracket estim consensu non-
 sg expens guidanc initi guidanc
bracket estim consensu vertex state previous
conserv guidanc reflect anticip revenu region reimburs
agreement place addit reimburs agreement could provid upsid
revenu howev except germani smaller market compani
make meaning progress reimburs negoti major eu market
franc england would slow growth current cf medicin may
complic tripl combin launch eu next year
progress made reimburs minor ou market vertex disclos call
current cf patient treat vertex drug end
compani updat total treat patient number updat
patient distribut geographi brand progress made ex-u
market germani scotland ireland australia reimburs battl
vertex sever import eu countri franc uk show sign
resolut favor price
robust phase data tripl combin revenu expect alreadi
high previous note vertex current valuat alreadi assum success launch
tripl combin regim could potenti treat total cf patient
vs current cf medicin compani confirm expect file one
two tripl combin regimen us eu vertex previous
guid file approv tripl combin delay
submiss slightli given excel phase data see minim risk secur
regulatori approv although delay file would advers affect expect
compani model current assum file tripl base manag
guidanc acceler review cycl would enabl earli launch
us current forecast revenu tripl combin grow
recent consensu first order analyt forecast launch
us tripl combin sale grow
non-cf pipelin make progress remain controversi
vertex made progress sever earli stage non-cf pipelin product
treatment antitrypsin defici advanc phase develop decemb
recent receiv fast track design fda collabor crsp develop
gene edit treatment sickl cell diseas beta thalassemia gain
traction well first patient enrol scd studi expect dose
addit vertex conduct multipl proof-of-concept studi acut musculoskelet
neuropath pain inhibitor although compani still seem equivoc
whether compound one backup advanc develop
compani view program develop plan reason effici given
avail potenti approv biomark circul level
cautiou view develop strategi
cf revenu larg in-lin expect price target
updat revenu expens forecast base recent quarter
commentari total revenu forecast decreas remain larg
unchang chang primarili base slightli slower
revenu trajectori kalydeco us sale revenu estim
partial off-set slightli higher symdeko ex-u sale revis total revenu
forecast consensu oper expens estim lower
due lower sg forecast partial off-set slightli higher estim base
chang pro-forma dilut ep estim virtual unchang decreas
virtual unchang increas revis
ep estim consensu consensu
revis price target maintain market perform rate
price target vertex base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl higher growth larg cap biopharmaceut compani price sale
multipl mid larg cap high growth biopharmaceut compani discount cash
flow dcf use current averag high growth larg cap biopharma multipl ep
nvo azn appli current ep estim discount
back year compani cost equiti give valu one year use
averag high growth larg cap biotech price-to-revenu multipl sale
appli revenu estim
post-tripl discount back year compani cost equiti give valu
one year lastli dcf valuat given wacc termin cash flow growth
rate give present valu averag three method current price
target
risk view outlook valuat vertex includ major chang price
reimburs coverag label competit posit kalydeco orkambi
compani main product today major risk disappoint delay failur
compani develop regulatori file novel tripl combin medicin
cystic fibrosi risk includ continu lack access reimburs vertex
medicin acceler success develop altern modul cftr
altern approach treat cf gene therapi final compani histori
spend much potenti earn expens diversifi acquisit could undermin
futur expect valu compani cf portfolio opportun better-than expect
perform includ realiz signific revenu compani current cf dual
combin market outsid us well acceler clinic develop tripl
sale non-gaap
non-gaap interest expens net
share count period basic
share count period dilut
guidanc
svb leerink research compani file zack factset consensu
svb leerink research compani file zack factset consensu
late stage pipelin program includ
late stage pipelin program exclud
brand
type event
event trial detail
date known
up/down
expect
phase iib dose rang studi patient
nda file cf patient year old
fda approv cf patient year old
svb leerink llc research compani file
million
product sale po adjust
tripl combin kalydeco second corrector full year sale
total product sale book
product sale po adjust
total product sale book
svb leerink llc research compani file
million
product sale direct product sale vertex
sale
forma tax excl nol benefit cash
 total revenu
sg total revenu
tax rate note differ pro forma due nol benefit cash
svb leerink llc partner research compani file
analysi stock price svb leerink target
method higher growth large-cap healthcar ep multipl svb leerink normal
current averag growth larg cap biopharma multipl ep nvo azn
svb leerink ep
impli price ep use current consensu high growth larg cap multipl
equiti
number period
impli one year target price approach
method discount futur valu normal revenu use mid larg cap biotech compar
averag growth larg cap mid cap biotech price-to-revenu multipl sale
impli vertex enterpris valu sale estimate mm
estimate net
impli vertex equiti valu mm
equiti
number period
impli vertex valu mm
impli one year target price approach
method dcf base current product po adjust outlook cf franchis use wacc
present valu late stage market product flow
net debt end
averag method
svb leerink llc research compani file factset
